InventisBio, Co., Ltd.SSE: 688382

(688382)"INVENTISBIO CO., LIMITED"Report for Q3 2026

Oct 30, 2026 · Issued by InventisBio, Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688382 · Oct 30, 2026 · 13 pages · Chinese

On 6ix: 6ix.com/news/688382inventisbio-co-limitedreport-for-q3-2026

InventisBio, Co., Ltd. on 6ix

Earlier from InventisBio

(688382)"INVENTISBIO CO., LIMITED"Announcement on Vesting Results for the Third Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan and Listing of SharesOct 28
Announcement on Convening the 2026 Semi-annual Performance BriefingAug 26
Announcement on the Satisfaction of Vesting Conditions for the 3rd Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive PlanAug 22
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 21
Announcement on Signing Quadripartite Supervision Agreement for Deposit of Raised Funds in Special AccountJul 23

Later from InventisBio

(688382)"INVENTISBIO CO., LIMITED"Announcement on the Phase III Clinical Study of Nomelcitinib (D-2570) for the Treatment of Moderate-to-Severe Plaque Psoriasis Achieving the Primary EndpointNov 2

All InventisBio news releases

Follow InventisBio into a list and get an email when it puts out news.

Follow InventisBio